Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.

被引：2
|
作者：
Daemen, Anneleen
Pankov, Aleksandr
Barkund, Shravani
Zhou, Haiying
Duff, Maureen
Johnson, Ann
Xu, Rongda
Multani, Pratik S.
Maneval, Edna Chow
Friedman, Lori
机构：
[1] 240 E Grand Ave, San Francisco, CA USA
[2] ORIC Pharmaceut, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3110
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3110
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
    McKean, Meredith
    Hutson, Thomas E.
    Piha-Paul, Sarina A.
    Micaily, Ida
    Liao, Mingxiang
    Humphreys, Robin
    Brock, Graham
    Sahr, Natasha
    Amber, Vian
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis
    Burns, Chris
    Cock, Terrie-Anne
    Bishop, Anthony
    Kruger, Nicole
    McCormack, Sarah
    Ananda, Sumitra
    Harris, Marion
    Joubert, Warren Lance
    Kim, Jin Won
    Lee, Choong-kun
    Lee, Woo Jin
    Lipton, Larissa Rachel
    Nagrial, Adnan
    Oh, Do-Youn
    Park, Joon Oh
    Pavlakis, Nick
    Lickliter, Jason
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors.
    Harb, Wael A.
    Johnson, Melissa Lynne
    Goldman, Jonathan Wade
    Weise, Amy M.
    Call, Justin Anthony
    Dudek, Arkadiusz Z.
    Gonzalez, Rene
    Cowey, C. Lance
    Eves, P. Taylor
    Gollerkeri, Ashwin
    Gainor, Justin F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
    Solomon, Benjamin J.
    Dagogo-Jack, Ibiayi
    Lee, Se-Hoon
    Boyer, Michael J.
    Ramalingam, Suresh S.
    Carcereny, Enric
    Felip, Enriqueta
    Han, Ji-Youn
    Hida, Toyoaki
    Hughes, Brett G. M.
    Kim, Sang -We
    Nishio, Makoto
    Seto, Takashi
    Okamoto, Tatsuro
    Zhang, Xiaoxi
    Martini, Jean -Francois
    Wang, Erjian
    De Beukelaer, Steven
    Bauer, Todd M.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (07):
  • [25] Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Marcus Noel
    Eileen M. O’Reilly
    Brian M. Wolpin
    David P. Ryan
    Andrea J. Bullock
    Carolyn D. Britten
    David C. Linehan
    Brian A. Belt
    Eric C. Gamelin
    Bishu Ganguly
    Donghua Yin
    Tenshang Joh
    Ira A. Jacobs
    Carrie T. Taylor
    Maeve A. Lowery
    Investigational New Drugs, 2020, 38 : 800 - 811
  • [26] Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Noel, Marcus
    O'Reilly, Eileen M.
    Wolpin, Brian M.
    Ryan, David P.
    Bullock, Andrea J.
    Britten, Carolyn D.
    Linehan, David C.
    Belt, Brian A.
    Gamelin, Eric C.
    Ganguly, Bishu
    Yin, Donghua
    Joh, Tenshang
    Jacobs, Ira A.
    Taylor, Carrie T.
    Lowery, Maeve A.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 800 - 811
  • [27] A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).
    Gordon, Michael S.
    Shapiro, Geoffrey
    Sarantopoulos, John
    Juric, Dejan
    Lu, Brian
    Chen, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity.
    Jain, Rohit K.
    Zhang, Jingsong
    Eroglu, Zeynep
    Creelan, Ben C.
    Brohl, Andrew Scott
    Shafique, Michael Rahman
    Gray, Jhanelle Elaine
    Muzaffar, Jameel
    Ida, Julia
    Lacevic, Mensura
    Kim, Youngchul
    Chung, Christine H.
    Sahebjam, Solmaz
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] First-in-human phase 1b study of ATRC-101, a patient-derived antibody with a tumor-specific target, as monotherapy or in combination with pembrolizumab, in patients with solid tumors.
    Benjamin, Jonathan E.
    Higgins, Nicholas
    Millward, Carl
    DeFalco, Jeff
    Manning-Bog, Amy
    Aydin, Iraz T.
    Zhang, Danhui
    Lippow, Shaun M.
    Scholz, Alexander
    Leung, Yvonne
    Zhu, Yanhong
    Sedello, Anna
    Rogers, Zane
    Dhawan, Ish K.
    Emerling, Daniel
    Robinson, William H.
    Serafini, Tito A.
    Greenberg, Norman M.
    CANCER RESEARCH, 2021, 81 (13)
  • [30] Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Prenen, Hans
    Lambert, Aurelien
    Geboes, Karen
    Blanc, Jean-Frederic
    de Coana, Yago Pico
    Enell-Smith, Karin
    Schultz, Lena
    Nordbladh, Karin
    Ellmark, Peter
    Ambarkhane, Sumeet
    Carlsson, Malin
    Cassier, Philippe
    CANCER RESEARCH, 2022, 82 (22) : 10 - 11
12345